PEL
MCID: PRM042
MIFTS: 55

Primary Effusion Lymphoma (PEL)

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Primary Effusion Lymphoma

MalaCards integrated aliases for Primary Effusion Lymphoma:

Name: Primary Effusion Lymphoma 53 59 17 72
Pel 53 59
Body Cavity-Based Lymphoma 59
Lymphoma, Aids-Related 72
Aids-Related Lymphoma 53

Characteristics:

Orphanet epidemiological data:

59
primary effusion lymphoma
Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

MESH via Orphanet 45 D054685
ICD10 via Orphanet 34 C83.8
UMLS via Orphanet 73 C1292753
Orphanet 59 ORPHA48686
UMLS 72 C0085090 C1292753

Summaries for Primary Effusion Lymphoma

MalaCards based summary : Primary Effusion Lymphoma, also known as pel, is related to human herpesvirus 8 and plasmablastic lymphoma. An important gene associated with Primary Effusion Lymphoma is IRF4 (Interferon Regulatory Factor 4), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Ketamine and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include b cells, endothelial and t cells, and related phenotypes are dyspnea and abdominal pain

Wikipedia : 75 Primary effusion lymphoma (PEL) is a B-cell lymphoma, presenting with a malignant effusion without a... more...

Related Diseases for Primary Effusion Lymphoma

Diseases related to Primary Effusion Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 209)
# Related Disease Score Top Affiliating Genes
1 human herpesvirus 8 32.8 IL6 BCL6
2 plasmablastic lymphoma 32.7 MYC BCL6
3 kaposi sarcoma 31.2 VEGFA MYC IL6 CASP8 AKT1
4 multicentric castleman disease 30.6 IL6 BCL6
5 diffuse large b-cell lymphoma 30.5 MYC IRF4 BCL6
6 castleman disease 30.5 VEGFA IL6 BCL6
7 acquired immunodeficiency syndrome 30.5 MYC IL6 BCL6
8 nodal marginal zone lymphoma 29.9 CASP3 BIRC5
9 plasmacytoma 29.9 MYC IRF4 IL6
10 gastric lymphoma 29.8 VEGFA BCL6
11 follicular lymphoma 29.8 MYC IRF4 BCL6
12 mature b-cell neoplasm 29.6 MYC IL6 BCL6
13 nasopharyngeal carcinoma 29.6 VEGFA MYC CASP3 AKT1
14 richter's syndrome 29.5 MYC IRF4
15 post-transplant lymphoproliferative disease 29.4 TNFSF10 IL6 CASP8
16 nervous system disease 29.4 VEGFA IL6 CASP3 AKT1
17 breast adenocarcinoma 29.0 MYC CASP8 AKT1
18 lymphoma, non-hodgkin, familial 28.6 MYC IRF4 CASP8 CASP3 BIRC5 BCL6
19 leukemia, acute myeloid 28.6 MYC CASP8 CASP3 AKT1
20 leukemia, chronic lymphocytic 28.5 TNFSF10 CASP8 CASP3 BCL6
21 burkitt lymphoma 28.3 MYC CASP8 CASP3 BIRC5 BCL6
22 myeloma, multiple 27.8 VEGFA MYC IRF4 IL6 CASP8 CASP3
23 lymphoma aids related 12.1
24 lymphoma 11.0
25 b-cell lymphoma 10.7
26 lymphoma, hodgkin, classic 10.6
27 sarcoma 10.6
28 spindle cell sarcoma 10.6
29 severe combined immunodeficiency 10.5
30 hemopericardium 10.5
31 pericardial effusion 10.5
32 spinal disease 10.3 VEGFA IL6
33 pharynx squamous cell carcinoma 10.3 CASP3 AKT1
34 encephalopathy, progressive, with or without lipodystrophy 10.3
35 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.3 MYC BCL6
36 blood group, globoside system 10.3 VEGFA IL6
37 cardiac tamponade 10.3
38 b-cell non-hodgkin lymphoma 10.3
39 poems syndrome 10.3 VEGFA IL6
40 immune deficiency disease 10.3
41 liver cirrhosis 10.3
42 colon lymphoma 10.3 IRF4 BCL6
43 hepatitis c virus 10.3
44 anaplastic large cell lymphoma 10.3
45 lymphoproliferative syndrome 10.3
46 combined t cell and b cell immunodeficiency 10.3
47 primary central nervous system lymphoma 10.3
48 macular retinal edema 10.2 VEGFA IL6
49 chromosomal triplication 10.2
50 central nervous system hematologic cancer 10.1 IRF4 BCL6

Graphical network of the top 20 diseases related to Primary Effusion Lymphoma:



Diseases related to Primary Effusion Lymphoma

Symptoms & Phenotypes for Primary Effusion Lymphoma

Human phenotypes related to Primary Effusion Lymphoma:

59 32 (show all 8)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dyspnea 59 32 hallmark (90%) Very frequent (99-80%) HP:0002094
2 abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002027
3 abdominal distention 59 32 hallmark (90%) Very frequent (99-80%) HP:0003270
4 abnormality of the peritoneum 59 32 hallmark (90%) Very frequent (99-80%) HP:0002585
5 pleural effusion 59 32 hallmark (90%) Very frequent (99-80%) HP:0002202
6 pericardial effusion 59 32 hallmark (90%) Very frequent (99-80%) HP:0001698
7 b-cell lymphoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0012191
8 immunodeficiency 59 32 frequent (33%) Frequent (79-30%) HP:0002721

GenomeRNAi Phenotypes related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.72 AKT1 BIRC5 CASP3 CASP8 CDK2 TNFSF10
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.72 AKT1 BIRC5 CASP3 CASP8 CDK2 TNFSF10
3 Increased cell death HMECs cells GR00103-A-0 9.35 BCL6 BIRC5 CASP3 CDK2 MYC

MGI Mouse Phenotypes related to Primary Effusion Lymphoma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.24 AKT1 BCL6 BIRC5 CASP3 CASP8 CDK2
2 hematopoietic system MP:0005397 10.22 AKT1 BCL6 BIRC5 CASP3 CASP8 CDK2
3 endocrine/exocrine gland MP:0005379 10.21 AKT1 BCL6 BIRC5 CASP3 CASP8 CDK2
4 cardiovascular system MP:0005385 10.2 AKT1 BCL6 CASP3 CASP8 CDK2 IL6
5 homeostasis/metabolism MP:0005376 10.2 AKT1 BCL6 BIRC5 CASP3 CASP8 CDK2
6 immune system MP:0005387 10.17 AKT1 BCL6 BIRC5 CASP3 CASP8 CDK2
7 growth/size/body region MP:0005378 10.15 AKT1 BCL6 CASP3 CASP8 CDK2 IL6
8 mortality/aging MP:0010768 10.02 AKT1 BCL6 BIRC5 CASP3 CASP8 CDK2
9 embryo MP:0005380 10 AKT1 BIRC5 CASP8 CDK2 MYC VEGFA
10 liver/biliary system MP:0005370 9.97 AKT1 BCL6 CASP8 CDK2 IL6 MYC
11 integument MP:0010771 9.95 AKT1 CASP3 CASP8 CDK2 IL6 MYC
12 muscle MP:0005369 9.86 AKT1 BCL6 CASP3 CASP8 CDK2 IL6
13 neoplasm MP:0002006 9.76 AKT1 CASP8 CDK2 IL6 IRF4 MYC
14 reproductive system MP:0005389 9.5 AKT1 BCL6 CASP3 CDK2 IL6 MYC
15 respiratory system MP:0005388 9.1 AKT1 BCL6 CASP3 CASP8 IL6 VEGFA

Drugs & Therapeutics for Primary Effusion Lymphoma

Drugs for Primary Effusion Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 184)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
3
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
4
Morphine Approved, Investigational Phase 3 57-27-2 5288826
5
Mercaptopurine Approved Phase 3 50-44-2 667490
6
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
7
Ondansetron Approved Phase 3 99614-02-5 4595
8
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
9
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
10
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
13 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
14 Anesthetics, Dissociative Phase 3
15 Hormones Phase 3
16 Anti-Bacterial Agents Phase 3
17 Anti-Infective Agents Phase 3
18 Antidotes Phase 3
19 Protective Agents Phase 3
20 Antiparasitic Agents Phase 3
21 Antiprotozoal Agents Phase 3
22 Gastrointestinal Agents Phase 3
23 Antiemetics Phase 3
24 Peripheral Nervous System Agents Phase 3
25 Antifungal Agents Phase 3
26 Autonomic Agents Phase 3
27 Antibodies Phase 3
28 Immunoglobulins Phase 3
29 Antibodies, Monoclonal Phase 3
30 Analgesics Phase 3
31 Neurotransmitter Agents Phase 3
32 Tranquilizing Agents Phase 3
33 Central Nervous System Depressants Phase 3
34 Psychotropic Drugs Phase 3
35 Narcotics Phase 3
36 Respiratory System Agents Phase 3
37 Analgesics, Opioid Phase 3
38 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
39 Antitussive Agents Phase 3
40 Micronutrients Phase 3
41 Trace Elements Phase 3
42 Vitamins Phase 3
43 Nutrients Phase 3
44 Anesthetics, Intravenous Phase 3
45 Excitatory Amino Acid Antagonists Phase 3
46 Anesthetics Phase 3
47 Anesthetics, General Phase 3
48 Excitatory Amino Acids Phase 3
49 Liver Extracts Phase 3
50 Serotonin Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Randomized Trial of CHOP Chemotherapy With or Without Rituximab (Chimeric Anti-CD20 Antibody) for HIV-Associated Non-Hodgkin's Lymphoma Completed NCT00003595 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
3 A Phase III Study of Large Cell Lymphomas in Children and Adolescents: Comparison of APO vs APO + IDMTX/HDARA-C and Continuous vs Bolus Infusion of Doxorubicin Completed NCT00002618 Phase 3 cytarabine;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;vincristine sulfate
4 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
5 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
6 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
7 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
8 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
9 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
10 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 A Phase I/II Study of the Safety and Feasibility of REVM10 or REVM10/ANTISENSE POL 1 Transduced Hematopoietic Stem Cells (HSC) in HIV-1 Related Non-Hodgkin's Lymphoma Patients Already Being Treated With High Dose Chemotherapy and Peripheral Blood Stem Cell Support Unknown status NCT00003942 Phase 1, Phase 2
12 Pilot Study Of PMitCEBO Plus G-CSF In Good-Prognosis HIV-Related Lymphoma Unknown status NCT00032149 Phase 1, Phase 2 cyclophosphamide;etoposide;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
13 Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL Unknown status NCT01016990 Phase 2 valproic acid
14 Treatment of HIV-Related Primary Central Nervous System Lymphoma (HIV-PCNSL): A Phase II Trial With Neoadjuvant Chemotherapy (High-Dose Methotrexate (MTX) Plus High-Dose Zidovudine) and Radiotherapy Unknown status NCT00003261 Phase 2 methotrexate;zidovudine
15 Prospective Non Randomized Study With Chemotherapy in Patients With Hodgkin's Disease and HIV Infection: "Stanford V Regimen" For "Low Risk" Patients, "EBVP Regimen" For "High Risk" Patients Unknown status NCT00003262 Phase 2 Stanford V regimen;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;mechlorethamine hydrochloride;prednisone;vinblastine sulfate;vincristine sulfate
16 Pilot Study of the Safety and Feasibility of Autologous Peripheral Blood Stem Cell Transplantation for Patients With Relapsed AIDS-Related Lymphoma Completed NCT00005824 Phase 2 busulfan;cyclophosphamide
17 A Phase II Study of Doxil (Liposomal Doxorubicin), Cyclophosphamide, Vincristine and Prednisone for AIDS-Related Systemic Lymphoma Completed NCT00003388 Phase 2 cyclophosphamide;cytarabine;methotrexate;pegylated liposomal doxorubicin hydrochloride;prednisone;vincristine sulfate
18 EPOCH Chemotherapy Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma Completed NCT00001563 Phase 2 EPOCH
19 Study of Promace-Cytabom With Trimethoprim Sulfamethoxazole, Zidovudine (AZT), and Granulocyte Colony Stimulating Factor (G-CSF) in Patients With AIDS-Related Lymphoma, Phase II Completed NCT00002571 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate;prednisone;trimethoprim-sulfamethoxazole;vincristine sulfate;Intrathecal cytarabine
20 Pilot Study in AIDS-Related Lymphomas Completed NCT00002524 Phase 2 Cisplatin;Cyclophosphamide;Cytarabine;Doxorubicin Hydrochloride (DOX);Etoposide;Fluorouracil;Ifosfamide;Leucovorin calcium;Methotrexate;Methylprednisolone;Pentamidine;Prednisone;Trimethoprim-Sulfamethoxazole;Vincristine Sulfate;Zidovudine (AZT)
21 High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT Completed NCT00858793 Phase 1, Phase 2
22 Feasibility Study of CO-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of Acquired Immunodeficiency Syndrome (AIDS)-Related Lymphoma Completed NCT00799136 Phase 2 R-EPOCH and cART
23 Phase II Evaluation of Gallium Nitrate (NSC 15200) in Non-Hodgkin's Lymphoma in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002578 Phase 2 cytarabine;gallium nitrate;leucovorin calcium;methotrexate
24 A Phase II Trial of 72-Hour Continuous Infusion Bleomycin as Salvage Therapy in AIDS-Related and Immunocompetent Non-Hodgkin's Lymphoma Completed NCT00003110 Phase 2
25 Dose-Modified Oral Combination Chemotherapy In Patients With Aids-Related Non-Hodgkin's Lymphoma In The United States And Africa Completed NCT00049439 Phase 2 cyclophosphamide;etoposide;lomustine;procarbazine hydrochloride
26 Primary Effusion Lymphoma: A Pilot Trial of Bevacizumab and Modified Dose-Adjusted Infusional CDE Chemotherapy Preceded by a Brief Pre-Phase Assessment of Targeted Oncolytic Virotherapy With Bortezomib, Zidovudine and Valganciclovir Completed NCT00217503 Phase 2 bortezomib;cyclophosphamide;doxorubicin hydrochloride;etoposide;ganciclovir;valganciclovir;zidovudine
27 Phase II Evaluation of Mitoguazone Dihydrochloride in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma Associated With Acquired Immunodeficiency Syndrome Completed NCT00002348 Phase 2 Mitoguazone
28 A Randomized Pre-Phase II Trial of Interleukin-2, Interleukin-12, or No Additional Therapy Following Response to Ifosfamide/Etoposide Chemotherapy for Refractory HIV-Associated Non-Hodgkin's Lymphoma Completed NCT00003575 Phase 2 etoposide;ifosfamide
29 Hydroxyurea Treatment of EBV-Associated Primary CNS Lymphoma in Children and Adults With AIDS Completed NCT00002940 Phase 2 hydroxyurea
30 First Line Treatment in HIV-related Large Cell Non Hodgkin Lymphoma at "High Risk", Including Early Consolidation With High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation Completed NCT01045889 Phase 2
31 A Phase II Trial Of Induction Therapy With Zidovudine, Interleukin-2, And Ganciclovir In The Treatment Of HIV Positive Primary Central Nervous System Lymphoma Completed NCT00006264 Phase 2 ganciclovir;zidovudine
32 A Phase II Trial of Doxil, Rituximab, Cyclophosphamide, Vincristine, and Prednisone (DR-COP) in Patients With Newly Diagnosed AIDS-Associated B-Cell Non-Hodgkin's Lymphoma Completed NCT00389818 Phase 2 cyclophosphamide;pegylated liposomal doxorubicin hydrochloride;prednisone;vincristine sulfate
33 Oral Combination Chemotherapy in the Treatment of AIDS-Associated Hodgkin's Disease Completed NCT00003114 Phase 2 cyclophosphamide;etoposide;lomustine;procarbazine hydrochloride
34 A Phase II Study of Alpha Interferon (alphaIFN) In HIV-Related Malignancies - A Pediatric Oncology Group Wide Study Completed NCT00002621 Phase 2
35 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
36 High Dose Chemotherapy With Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients (BMT CTN #0803) Completed NCT01141712 Phase 2 BCNU;Etoposide;Cytarabine;Melphalan
37 High Dose Chemotherapy and Autologous Peripheral Stem Cell Transplantation for HIV Lymphomas: A Phase IIA Study of Comparative Marking Using a Ribozyme Gene and a Neutral Gene Completed NCT00002221 Phase 2 Peripheral blood stem cells
38 RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
39 Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy Completed NCT00255749 Phase 2
40 A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
41 An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune T-Lymphocytes Derived From a Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases Completed NCT00002663 Phase 1, Phase 2
42 Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma Completed NCT00392834 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;liposomal cytarabine;methotrexate;therapeutic hydrocortisone;vincristine sulfate
43 Phase I/II Study of Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R(2)) In Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma Recruiting NCT02911142 Phase 1, Phase 2 Lenalidomide;Rituximab;Prednisone;Etopside;Doxorubicin;Vincristine;Cyclophosphamide
44 AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy Recruiting NCT00267865 Phase 2 Methotrexate;Rituximab;Leucovorin
45 Short-Course EPOCH-Rituximab in Untreated CD-20+ HIV-Associated Lymphomas Recruiting NCT00006436 Phase 2 EPOCH
46 Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy With Concomitant Antiretroviral Therapy in Patients With HIV-Associated Lymphoma in Sub-Saharan Africa Active, not recruiting NCT01775475 Phase 2 cyclophosphamide;doxorubicin hydrochloride;vincristine sulfate;prednisone;lomustine;etoposide;cyclophosphamide;procarbazine hydrochloride
47 A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma Active, not recruiting NCT00392990 Phase 2 Regimen A;Regimen B
48 Multicenter, Open Label, Phase II Trial to Evaluate the Efficacy and Safety of Treatment With Rituximab + CHOP Regimen in Patients With HIV Related Non-Hodgkin’s Lymphomas. ANRS 085 Rituximab Terminated NCT00126243 Phase 2 rituximab;CHOP
49 Phase II Study of Induction Therapy Comprising Etoposide, Methylprednisolone, Cytarabine, and Cisplatin (ESHAP) Followed by Consolidation Therapy Comprising Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma Withdrawn NCT00310128 Phase 2 cisplatin;cytarabine;etoposide;methylprednisolone;rituximab;yttrium Y 90 ibritumomab tiuxetan
50 A Phase II Study of Phenylbutyrate and Valganciclovir in Epstein-Barr Virus Positive Tumors Withdrawn NCT00387530 Phase 2 oral sodium phenylbutyrate;valganciclovir

Search NIH Clinical Center for Primary Effusion Lymphoma

Genetic Tests for Primary Effusion Lymphoma

Anatomical Context for Primary Effusion Lymphoma

MalaCards organs/tissues related to Primary Effusion Lymphoma:

41
B Cells, Endothelial, T Cells, Liver, Brain, Bone, Bone Marrow

Publications for Primary Effusion Lymphoma

Articles related to Primary Effusion Lymphoma:

(show top 50) (show all 1196)
# Title Authors PMID Year
1
The current state of human immunodeficiency virus-associated lymphoma in Japan: a nationwide retrospective study of the Japanese Society of Hematology Blood Disease Registry. 38
31111394 2019
2
Novel Virus Related to Kaposi's Sarcoma-Associated Herpesvirus from Colobus Monkey. 38
31310220 2019
3
EphA7 Functions as Receptor on BJAB Cells for Cell-to-Cell Transmission of the Kaposi's Sarcoma-Associated Herpesvirus and for Cell-Free Infection by the Related Rhesus Monkey Rhadinovirus. 38
31118261 2019
4
Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma. 38
31346082 2019
5
CRISPR/Cas9-mediated Knockout and In Situ Inversion of ORF57 Gene from All Copies of The KSHV Genome in BCBL-1 Cells. 38
31413125 2019
6
Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir. 38
31351487 2019
7
Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma. 38
31300418 2019
8
A herpesvirus transactivator and cellular POU proteins extensively regulate DNA binding of the host Notch signaling protein RBP-Jk to the virus genome. 38
31308175 2019
9
Association of polymorphisms in NFκB1 promoter and NFκBIA gene with the development of antibodies against HHV-8 in HIV-infected individuals. 38
31344550 2019
10
Human Herpes-8 virus copy to cell ratio: A diagnostic tool in primary effusion lymphoma. 38
30991238 2019
11
Expression of PD-1 and PD-Ls in Kaposi's sarcoma and regulation by oncogenic herpesvirus lytic reactivation. 38
31394407 2019
12
Kaposi Sarcoma in Association With an Extracavitary Primary Effusion Lymphoma Showing Unusual Intravascular Involvement: Report of a Case Harboring a FAM175A Germline Mutation. 38
31361614 2019
13
miRNAs and their roles in KSHV pathogenesis. 38
30951791 2019
14
The landscape of transcription initiation across latent and lytic KSHV genomes. 38
31188901 2019
15
Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells. 38
30962205 2019
16
Latent infection with Kaposi's sarcoma-associated herpesvirus enhances retrotransposition of long interspersed element-1. 38
30770900 2019
17
Kaposi's sarcoma-associated herpesvirus vIRF2 protein utilizes an IFN-dependent pathway to regulate viral early gene expression. 38
31059555 2019
18
Indolent primary effusion lymphoma-like lymphoma in the pericardium: A case report and review of the literature. 38
31073346 2019
19
Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma. 38
30671911 2019
20
Extracavitary primary effusion lymphoma (PEL) presenting as bilateral adrenal gland involvement in an HIV-positive patient. 38
30328487 2019
21
Viral, immunologic, and clinical features of primary effusion lymphoma. 38
30782610 2019
22
Towards Better Understanding of KSHV Life Cycle: from Transcription and Posttranscriptional Regulations to Pathogenesis. 38
31025296 2019
23
Insulin-Like Growth Factor 2 Receptor Expression Is Promoted by Human Herpesvirus 8-Encoded Interleukin-6 and Contributes to Viral Latency and Productive Replication. 38
30541844 2019
24
Human herpesvirus 6, 7, and 8 in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. 38
30844089 2019
25
High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma. 38
31253594 2019
26
Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma. 38
30837213 2019
27
Kaposi sarcoma-associated herpesvirus/human herpesvirus 8-associated lymphoproliferative disorders. 38
30610029 2019
28
Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues. 38
30380402 2019
29
Primary effusion lymphoma of the pleural space: Report of a rare complication of cardiac transplant with review of the literature. 38
30276937 2019
30
Human IFIT proteins inhibit lytic replication of KSHV: A new feed-forward loop in the innate immune system. 38
30779786 2019
31
Cell Type-Specific Interferon-γ-mediated Antagonism of KSHV Lytic Replication. 38
30787356 2019
32
Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma. 38
30782662 2019
33
Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. 38
30764603 2019
34
Epstein-Barr Virus-Positive CD20- and CD45-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge. 38
29968492 2019
35
Capsaicin Induces Apoptosis in KSHV-Positive Primary Effusion Lymphoma by Suppressing ERK and p38 MAPK Signaling and IL-6 Expression. 38
30838176 2019
36
[Human herpes virus 8-negative primary effusion lymphoma-like lymphoma recurring as a tumor adjacent to the left atrium]. 38
31068519 2019
37
Molecular Biology of KSHV in Relation to HIV/AIDS-Associated Oncogenesis. 38
30523620 2019
38
Capsaicin Induces ATF4 Translation with Upregulation of CHOP, GADD34 and PUMA. 38
31366879 2019
39
AIDS-Associated Malignancies. 38
30523619 2019
40
[Replication Machinery of Kaposi's Sarcoma-associated Herpesvirus and Drug Discovery Research]. 38
30606932 2019
41
Discovery of Kaposi's sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA. 38
30455306 2018
42
Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV. 38
30607128 2018
43
Cytotoxic Drugs Activate KSHV Lytic Cycle in Latently Infected PEL Cells by Inducing a Moderate ROS Increase Controlled by HSF1, NRF2 and p62/SQSTM1. 38
30586869 2018
44
Age and CD20 Expression Are Significant Prognostic Factors in Human Herpes Virus-8-negative Effusion-based Lymphoma. 38
30273194 2018
45
RIG-I like receptor sensing of host RNAs facilitates the cell-intrinsic immune response to KSHV infection. 38
30451863 2018
46
Biology and management of primary effusion lymphoma. 38
30154110 2018
47
Epstein-Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus. 38
30429324 2018
48
33-year-old HIV-positive patient presenting with primary effusion lymphoma. 38
30455942 2018
49
Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Renders B Cells Hyperresponsive to Secondary Infections. 38
30021906 2018
50
Treatment and Survival of Patients With Primary Effusion Lymphoma in the Netherlands: A Population-based Analysis, 2002-2015. 38
30887007 2018

Variations for Primary Effusion Lymphoma

Copy number variations for Primary Effusion Lymphoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 25103 1 184000000 197500000 Gain primary effusion lymphomas
2 189792 4 78400000 172200000 Gain primary effusion lymphomas
3 239813 8 41800000 84900000 Gain primary effusion lymphomas
4 262574 X 37500000 98200000 Gain primary effusion lymphomas

Expression for Primary Effusion Lymphoma

Search GEO for disease gene expression data for Primary Effusion Lymphoma.

Pathways for Primary Effusion Lymphoma

Pathways related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 88)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 VEGFA TNFSF10 MYC IL6 CDK2 CASP8
2
Show member pathways
13.93 VEGFA MYC IRF4 IL6 CASP8 CASP3
3
Show member pathways
13.78 VEGFA TNFSF10 MYC IL6 CDK2 CASP8
4
Show member pathways
13.24 VEGFA MYC IRF4 IL6 CASP3 BIRC5
5
Show member pathways
13.23 TNFSF10 IL6 CASP8 CASP3 AKT1
6
Show member pathways
13.21 VEGFA IL6 CASP8 CASP3 AKT1
7
Show member pathways
12.89 VEGFA MYC IL6 CDK2 CASP8 CASP3
8
Show member pathways
12.86 VEGFA TNFSF10 IL6 CASP8 CASP3 AKT1
9
Show member pathways
12.8 VEGFA MYC IL6 CDK2 CASP8 CASP3
10
Show member pathways
12.79 VEGFA MYC CDK2 CASP3 BIRC5 AKT1
11
Show member pathways
12.73 MYC IL6 BIRC5 AKT1
12 12.7 VEGFA MYC CASP8 CASP3 AKT1
13
Show member pathways
12.68 TNFSF10 MYC IRF4 CASP8 CASP3 BIRC5
14
Show member pathways
12.65 MYC CDK2 CASP8 CASP3
15
Show member pathways
12.64 VEGFA IL6 CDK2 AKT1
16
Show member pathways
12.61 VEGFA TNFSF10 CASP8 CASP3 AKT1
17
Show member pathways
12.56 MYC IL6 BIRC5 AKT1
18
Show member pathways
12.56 VEGFA TNFSF10 CASP8 CASP3 AKT1
19 12.48 VEGFA MYC IL6 CDK2 CASP8 CASP3
20 12.41 MYC CDK2 BIRC5 AKT1
21
Show member pathways
12.38 MYC IRF4 BCL6 AKT1
22
Show member pathways
12.36 MYC CDK2 CASP8 CASP3
23
Show member pathways
12.31 IL6 CASP8 CASP3 AKT1
24
Show member pathways
12.28 TNFSF10 CASP8 CASP3 AKT1
25 12.28 VEGFA MYC CASP3 AKT1
26 12.24 CDK2 CASP8 CASP3
27
Show member pathways
12.24 MYC IRF4 IL6 AKT1
28
Show member pathways
12.24 VEGFA CDK2 CASP3 AKT1
29
Show member pathways
12.21 CASP8 CASP3 AKT1
30 12.21 MYC IL6 BCL6
31 12.21 TNFSF10 MYC CASP8 CASP3 BIRC5
32
Show member pathways
12.21 TNFSF10 CDK2 CASP8 CASP3 AKT1
33
Show member pathways
12.19 MYC CDK2 CASP3 AKT1
34 12.19 IL6 CASP8 CASP3 AKT1
35
Show member pathways
12.17 IL6 CASP8 AKT1
36 12.14 VEGFA IL6 CASP3
37 12.12 MYC IL6 CDK2 AKT1
38
Show member pathways
12.1 MYC CASP3 AKT1
39 12.1 MYC CDK2 CASP3 AKT1
40
Show member pathways
12.08 CASP8 CASP3 AKT1
41 12.06 VEGFA MYC IL6 CASP3 BIRC5 AKT1
42
Show member pathways
12.04 MYC CDK2 AKT1
43 12.04 VEGFA MYC IL6
44
Show member pathways
12.04 TNFSF10 MYC IL6 AKT1
45
Show member pathways
12.01 CASP8 CASP3 AKT1
46
Show member pathways
12.01 CASP8 CASP3 AKT1
47
Show member pathways
12.01 TNFSF10 IL6 CDK2 BCL6 AKT1
48
Show member pathways
12 CASP8 CASP3 AKT1
49 11.99 VEGFA MYC CDK2 CASP8 CASP3 AKT1
50 11.98 MYC IL6 CDK2 CASP3

GO Terms for Primary Effusion Lymphoma

Cellular components related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.56 MYC IRF4 CDK2 CASP8 CASP3 BIRC5
2 death-inducing signaling complex GO:0031264 8.62 CASP8 CASP3

Biological processes related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.93 TNFSF10 CASP8 CASP3 BIRC5 AKT1
2 positive regulation of gene expression GO:0010628 9.9 VEGFA MYC IL6 AKT1
3 positive regulation of transcription, DNA-templated GO:0045893 9.89 MYC IRF4 IL6 CDK2 AKT1
4 regulation of apoptotic process GO:0042981 9.81 CASP8 BIRC5 BCL6 AKT1
5 cellular response to DNA damage stimulus GO:0006974 9.8 MYC CDK2 CASP3 BCL6 AKT1
6 positive regulation of apoptotic process GO:0043065 9.77 TNFSF10 IL6 CASP3 BCL6 AKT1
7 cellular response to hypoxia GO:0071456 9.76 VEGFA MYC AKT1
8 response to estradiol GO:0032355 9.75 MYC CASP8 CASP3
9 positive regulation of cell proliferation GO:0008284 9.73 VEGFA MYC IL6 CDK2 BIRC5 AKT1
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.7 VEGFA IL6 AKT1
11 response to tumor necrosis factor GO:0034612 9.65 CASP8 CASP3
12 response to antibiotic GO:0046677 9.65 CASP8 CASP3
13 positive regulation of DNA binding GO:0043388 9.64 MYC IRF4
14 positive regulation of mesenchymal cell proliferation GO:0002053 9.63 VEGFA MYC
15 endocrine pancreas development GO:0031018 9.63 IL6 AKT1
16 cell migration involved in sprouting angiogenesis GO:0002042 9.62 VEGFA AKT1
17 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.62 TNFSF10 CASP8
18 positive regulation of glial cell proliferation GO:0060252 9.61 MYC IL6
19 macrophage differentiation GO:0030225 9.61 VEGFA CASP8
20 positive regulation of smooth muscle cell proliferation GO:0048661 9.61 MYC IL6 AKT1
21 striated muscle cell differentiation GO:0051146 9.59 CASP3 AKT1
22 positive regulation of mitochondrial membrane potential GO:0010918 9.57 MYC AKT1
23 positive regulation of cellular component movement GO:0051272 9.56 VEGFA BCL6
24 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.55 TNFSF10 CASP8
25 execution phase of apoptosis GO:0097194 9.5 CASP8 CASP3 AKT1
26 negative regulation of apoptotic process GO:0043066 9.5 VEGFA MYC IL6 CASP3 BIRC5 BCL6
27 T-helper 17 cell lineage commitment GO:0072540 9.48 IRF4 IL6
28 response to cobalt ion GO:0032025 9.46 CASP8 CASP3
29 cellular response to organic cyclic compound GO:0071407 9.46 MYC CASP8 CASP3 AKT1
30 cytokine-mediated signaling pathway GO:0019221 9.23 VEGFA MYC IRF4 IL6 CASP3 BIRC5
31 positive regulation of transcription by RNA polymerase II GO:0045944 10.04 VEGFA MYC IRF4 IL6 AKT1

Molecular functions related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 death receptor binding GO:0005123 9.26 CASP8 CASP3
2 cysteine-type endopeptidase activity involved in apoptotic process GO:0097153 9.16 CASP8 CASP3
3 identical protein binding GO:0042802 9.1 VEGFA TNFSF10 CASP8 BIRC5 BCL6 AKT1
4 cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097199 8.96 CASP8 CASP3
5 protein binding GO:0005515 10.06 VEGFA TNFSF10 MYC IRF4 IL6 CDK2

Sources for Primary Effusion Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....